Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance
| Status: | Completed |
|---|---|
| Conditions: | Endocrine |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 9/22/2018 |
| Start Date: | September 2013 |
| End Date: | May 2018 |
Rates of cardiovascular disease and diabetes are more than 2-fold greater in HIV infected
people than the general population. Protease inhibitor booster antiretroviral therapy
(PI-ART) which is used by ~50% of HIV infected people in the USA is an established risk
factor for diabetes. Tauroursodeoxycholic acid (TUDCA), a naturally occurring bile salt,
improves insulin sensitivity in HIV uninfected subjects, although the mechanisms for these
benefits are unclear. This study will explore the hypothesis that TUDCA will improve insulin
action in people with HIV who are receiving PI-ART. Further, this project will clarify the
molecular mechanisms responsible for these improvements potentially benefiting society,
irrespective of HIV status.
people than the general population. Protease inhibitor booster antiretroviral therapy
(PI-ART) which is used by ~50% of HIV infected people in the USA is an established risk
factor for diabetes. Tauroursodeoxycholic acid (TUDCA), a naturally occurring bile salt,
improves insulin sensitivity in HIV uninfected subjects, although the mechanisms for these
benefits are unclear. This study will explore the hypothesis that TUDCA will improve insulin
action in people with HIV who are receiving PI-ART. Further, this project will clarify the
molecular mechanisms responsible for these improvements potentially benefiting society,
irrespective of HIV status.
The purpose of this study is to determine if, and through which mechanisms,
tauroursodeoxycholic acid improves insulin sensitivity in subjects with protease-inhibitor
associated insulin resistance.
The investigators will perform body composition analysis by using a DEXA machine, liver fat
measurement by using an MRI, and hyperinsulinemic euglycemic clamp procedures in 48 HIV
infected, insulin-resistant/prediabetic subjects before and after 30 days of treatment with
tauroursodeoxycholic acid or matching placebo. Biopsies of adipose tissue and skeletal muscle
will be taken during fasting conditions and during insulin infusion, before and after
treatment to measure markers of endoplasmic reticulum stress and thyroid hormone deiodinase.
Outcome measures:
The primary outcome measures will be change in glucose clearance during insulin infusion,
change in markers of endoplasmic reticulum stress and change in content of D2 in muscle.
tauroursodeoxycholic acid improves insulin sensitivity in subjects with protease-inhibitor
associated insulin resistance.
The investigators will perform body composition analysis by using a DEXA machine, liver fat
measurement by using an MRI, and hyperinsulinemic euglycemic clamp procedures in 48 HIV
infected, insulin-resistant/prediabetic subjects before and after 30 days of treatment with
tauroursodeoxycholic acid or matching placebo. Biopsies of adipose tissue and skeletal muscle
will be taken during fasting conditions and during insulin infusion, before and after
treatment to measure markers of endoplasmic reticulum stress and thyroid hormone deiodinase.
Outcome measures:
The primary outcome measures will be change in glucose clearance during insulin infusion,
change in markers of endoplasmic reticulum stress and change in content of D2 in muscle.
Inclusion Criteria:
- HIV+
- receiving protease inhibitor containing antiretroviral therapy for >6 months
- Undetectable viral load
- insulin resistant
1. impaired fasting glucose (fasting blood glucose>100mg/dl)
2. impaired glucose tolerance (blood glucose >140mg/dl at 2 hours during oral
glucose tolerance testing).
- abstained from medications that affect glucose (e.g. prednisone, growth hormone)
- stable medications for >3 months
Exclusion Criteria:
- weight loss of >5% of body weight in prior 6 months
- active gastrointestinal disease (gallstones, pancreatitis, hepatitis, diarrhea)
- use of anti-diabetic medications
- cardiovascular disease (uncontrolled hypertension, heart attack, heart failure, prior
endocarditis)
- history of or active substance abuse
- blood clotting disorder or taking medications that affect blood clotting (e.g.
coumadin, warfarin)
- pregnant, planning to become pregnant or lactating
- unable to give informed consent
We found this trial at
1
site
660 S Euclid Ave
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
Click here to add this to my saved trials
